Introduction: The risk of abortion is known to be high in women with essential 20 thrombocythemia (ET). However, a few studies have focused on the risk of stillbirth 21 among fetuses reaching gestational age compatible with life. 22
Introduction 42
Essential thrombocythemia (ET) is a clonal myeloproliferative disorder characterized by 43 sustained increase in platelet number (> 450×10 9 /L) and tendency for thromboembolism. 44
As ET is more common in women and is the most common myeloproliferative disorder 45 in women of childbearing age, its incidence being 0.6 -2.5/100,000 patients/year, 46 although the median age at diagnosis is 65 -70 years [1, 2] , obstetricians may 47 encounter pregnant women with diagnosed ET. 48
49
Most reports suggest that the risk of fetal loss before reaching gestational age 50 compatible with life is several fold higher among women with ET than in the general 51 population [1, [3] [4] [5] [6] [7] . Previous review articles dealing with retrospective and prospective 52 cohort studies including single cases or small number of patients [5] , case series reports 53 including six or more consecutive patients or at least 10 pregnancies [6, 7] suggested 54 that the risk of fetal loss was high during the second trimester or after fetal maturation 55 compatible with life. However, it is somewhat unclear whether the risk of fetal loss is 56 high among fetuses with gestational week (GW) 24 or more [1] [2] [3] [4] [5] [6] [7] . 57
58
This study was conducted to determine whether the risk of stillbirth at and after GW 24 59 was higher in women with ET than in the general population. 60
61

METHODS 62
This study was conducted with the approval of the Ethics Committee of Hokkaido 63 University Hospital, a tertiary teaching hospital managing mainly high-risk pregnant 64 women. Medical charts of all pregnant women with diagnosed ET receiving care at 65
Hokkaido University Hospital during the study period between January 2003 and June 66 2013 were reviewed. In addition, we reviewed reports in the English literature dealing 67
with outcomes of more than 20 pregnancies complicated with ET. Case reports were 68 excluded from the present analysis because of the publication bias inherent in such 69 reports. 70 71
Abstraction of pregnant women with ET at Hokkaido University Hospital 72
A total of nine pregnancies in four women with diagnosed ET were abstracted from the 73 database of discharge summaries at the Obstetric ward of Hokkaido University Hospital 74 during the study period between January 2003 and June 2013. Medical charts of these 75 women were reviewed focusing on the outcome of pregnancy. All nine pregnancies 76 were booked at their beginning of pregnancies at which time no ominous signs were 77 present regarding pregnancy outcome. [11], also at Mayo Clinic, included patients discussed with in these two reports. Another 87 report by Passamonti et al. [16] was also excluded because the majority of patients had 88 already been described in a previous report by Passamonti [10] in which outcomes of 89 pregnancies were well presented. Thus, pregnant women with ET presented in six 90 reports [8-13], after excluding those presented in three reports [14-16], were considered 91 entirely different populations, without double-counting the same individuals with ET. 92
The pregnancy outcomes of women with ET presented in these six reports [8] [9] [10] [11] [12] [13] were 93 reviewed. Three outcome categories were set in this study: spontaneous abortion, 94
including ectopic pregnancy and preterm delivery before GW 24; stillbirth at and after 95 GW 24; and live birth (LB). Outcome classification was difficult in two of the six 96 reports [11, 12] . Three fetal losses were reported to have occurred during the second 97 trimester, but the GWs at which fetal losses occurred were not specified in the report by 98
Gangat et al. [11] in which there was no stillbirth category. These three fetal losses [11] 99 were assumed to have occurred before GW 24 to avoid overestimation of the number of 100 stillbirths at and after GW 24 in this study. In a report by Melillo et al., [12] there were 101 three adverse outcome categories, i.e., spontaneous abortion at GW≤ 12, spontaneous 102 abortion at GW > 12, and stillbirth with no mention of the GW at which stillbirth 103 occurred. We assumed that "stillbirth" in the report by Melillo et al. [12] occurred at or 104 after GW 24 in this study. 105
Risk estimation of stillbirth among Japanese fetuses at and after GW 22 107
The Japanese Ministry of Health, Labor, and Welfare releases vital statistics of Japan 108 yearly including the number of infants with live birth and stillbirth [17] . These data 109 allowed us to assess the risk of stillbirth among fetuses at and after GW 22 but not 110 fetuses at and after GW 24. 111
112
Results 113
ET cases at our institution 114
Of the nine pregnancies receiving care at our hospital, six resulted in live birth, two in 115 miscarriage during the first trimester, and one in stillbirth (intrauterine fetal death at 116 GW 35) ( Table 1) The stillbirth rate (per 1000 births including live births and stillbirths) at and after GW 149 22 decreased from 5.5 to 3.3 over the past two decades (Table 3) This study was conducted to determine whether the risk of stillbirth was higher among 154 women diagnosed with ET, focusing on the outcome of pregnancies that reached 155 mid-gestation in which viable infants are expected; the results indicated that women 156 with ET had a more than 10-fold higher risk of stillbirth after reaching GW 24 157 compared with the general population. 158
159
We experienced one case of stillbirth, occurring at GW 35, among seven ET 160 pregnancies beyond GW 23 (Table 1) , raising questions regarding the outcome of viable 161 infants carried by women with ET. This prompted us to search the literature regarding 162 the outcomes of pregnancies complicated with ET. Among six reports dealing with more 163 than 20 pregnancies reviewed in this study [8] [9] [10] [11] [12] [13] , four reported one to six cases with 164 stillbirth, a total of 14 stillbirth cases (Table 2) , occurring at or after GW 24 [8-10,12]. 165
The frequency of stillbirth ranged from 3.8% (1/26) to 26% (6/23) in four reports 166
[8-10,12], and overall stillbirth rate was 5.3% (14/264) among 264 women with GW ≥ 167 24 presented in the six reports [8] [9] [10] [11] [12] [13] . As expected based on our experience, stillbirths 168
were rare among women with GW ≥ 22 in Japan, accounting for only approximately 169 0.4% of all births during the past 20 years (Table 3) . As prospective risk of stillbirth 170 decreases with advancing gestation [19] , the risk of stillbirth is lower in women with 7 GW ≥ 24 than GW ≥ 22 [19] . Thus, the present study strongly suggested that women 172 with ET had a markedly increased risk of stillbirth compared with the general 173 population (more than 10-fold, 5.3% for women with ET vs. less than 0.4% for the 174 Japanese general population). Incidence of stillbirth in other area/countries are as In an attempt to avoid publication bias, the present study included only case series 181 reports that dealt with more than 20 pregnancies. However, the absolute risk of 5.3% for 182 stillbirth at and after GW 24 in this study was consistent with that of 5.0% at and after 183 GW 28 in a previous review article that dealt with reports including six or more 184 consecutive patients or at least 10 pregnancies [7] . In another review article that dealt 185 with case series reports including six or more consecutive patients, stillbirth risk is 186 11.3% for fetuses beyond the first trimester [6]. In practice guidelines by the Italian 187
Society of Experimental Hematology and the Italian Group for Bone Marrow 188
Transplantation, the outcome of pregnancies is described as follows "Overall, 204 of the 189 461 pregnancies had an unsuccessful outcome (44%), which is about three-fold higher 190 than in the general population" [5]. Fetal loss occurring at and after GW 22 accounts for 191 approximately 15% of all pregnancy loss in Japan [17]. If we assumed that pregnancy 192 loss at and after GW 24 accounted for 15% of all pregnancy loss, stillbirth rate at and 193 after GW 24 would be 6.6% in the Italian study [5] . In a recent review article referring 194 to treatment and outcome of pregnancy [4], it is clearly stated that complications such as 195 intrauterine growth retardation, stillbirth, and preeclampsia occur more frequently in 196 women with ET. Thus, maternity-service providers need to be cognizant that 197 approximately one in 20 fetuses carried by mothers with ET die in utero beyond GW 23. 198
199
Although low-dose aspirin was given in all nine pregnancies of four women with ET at 200 our hospital, whether the use of aspirin or cytoreductive agents, such as an interferon α, 201 a recommended agent during pregnancy [4, 22, 23] , can improve pregnancy outcome is 202 uncertain at present [4, 22] . However, as aspirin use in pregnancy is safe for both mother 203 and fetus [24] , most authors recommend the use of low-dose aspirin unless otherwise 204 8 contraindicated [3, 4, 22] . In addition, anticoagulation therapy is considered for all 205 women with ET for 6 weeks postpartum [22] or with a history of thrombosis or 206 recurrent pregnancy loss [3, 4] . Finazzi [22] defines high-risk women as those with 207 previous severe pregnancy complications, such as more than two first-trimester fetal 208 losses or at least one second-or third-trimester fetal loss, birth weight < 5 th percentile of 209 gestation, preeclampsia, or stillbirth, and states that low molecular weight heparin 210 throughout all pregnancy is indicated for prophylaxis of deep vein thrombosis and to 211 reduce fetal morbidity in such high-risk women with ET [22]. Maternal death from 212 pulmonary thromboembolism in Case 4 at our hospital may have been avoided with 213 such anticoagulation therapy, although evidence is lacking. 214
215
In conclusion, women with ET had a markedly elevated risk of stillbirth at and after 216 GW 24 compared to the general population; the absolute risk of stillbirth was 5.3% 217 among women with ET beyond GW 23 based on a literature review, while its risk is less 218 than 0.5% in most countries. This suggested the possibility that intensified monitoring 219 of fetal wellbeing may improve outcome, although evidence is still lacking. 220 221
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